Pheochromocytoma (PHEO) and Paraganglioma (PGL)Karel Pacak, David Taďeb This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment. |
Common terms and phrases
ablation activity addition adrenal analysis assessed associated biochemical blood pressure Cancer catecholamine cause characterization chromaffin cells Clin clinical cluster combined compared CrossRef CrossRef][PubMed detection diagnosis disease dose effect Endocrinol et al evaluation expression factors Figure follow-up function genes genetic germline glucose heart higher human hypertension hypoxia identified imaging increased Italy lead lesions levels malignant measured Medical Metab metastatic mice molecular mouse mutations myocardial infarction neck neuroendocrine normal observed Pacak pathways patients performed PET/CT phenotype PHEO pheochromocytoma and paraganglioma plasma positive postoperative potential PPGL present primary protein PubMed range receptor regulation reported resection response risk role samples SDHB SDHD secretion sequencing showed signaling significant somatic specific surgery symptoms syndrome Table testing therapy tissue treated treatment tumor University variant volume